There is a low but increased risk of optic nerve disorders in patients with type 2 diabetes prescribed semaglutide or ...

GLP-1RAs were associated with a reduced risk for neurodegenerative and cerebrovascular diseases in type 2 diabetes and obesity.

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

That’s double the 16% who reached that goal on semaglutide. A smaller group—almost 20%—on tirzepatide even lost 30% or more of their starting weight, compared to only 6.9% on semaglutide.

To assess the efficacy of tirzepatide compared with semaglutide in achieving standard and intensive cardiometabolic targets among adults with T2D, researchers conducted a post hoc analysis of the ...

The study included 7881 patients: 6109 and 1772 received semaglutide and tirzepatide, respectively; 80.8% had low maintenance dosages.

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

A study published in JAMA Network, by the Case Western Reserve University examined about 15,11,637 eligible participants with ...

Viking Therapeutics (VKTX 5.71%) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting ...

Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy are facing a ...